CION Ameerpet
Childhood non-Hodgkin lymphoma is fast-growing but highly treatable. This guide for parents explains the common types of paediatric NHL, the warning signs, how it is diagnosed, and how CION coordinates a child's care as a bridge into dedicated paediatric cancer services.
Non-Hodgkin lymphoma (NHL) is a cancer that starts in the lymphocytes — the white blood cells of the immune system — and grows in the lymph nodes and other lymphatic tissue. In children it behaves very differently from the disease in adults: childhood non hodgkin lymphoma is usually high-grade and fast-growing, and can involve the abdomen, chest, bone marrow or central nervous system. The reassuring flip side is that paediatric NHL is also very responsive to treatment, and outcomes today are good.
Because nhl in children can move quickly, recognising it early and confirming the exact type matters enormously. The type — Burkitt, lymphoblastic, diffuse large B-cell or anaplastic large-cell lymphoma — decides which established protocol a child is treated on. This page explains those types, the warning signs, how the diagnosis is made, and what care looks like. For a broader introduction, read our overview of lymphoma in children, and see the main lymphoma hub.
CION coordinates paediatric NHL care as a bridge into dedicated childhood-cancer services — see our Pediatric Cancer hub. You can also Book Free Consultation to discuss your child's reports with our team.
Lymphoma is the third most common cancer in children, after leukaemias and brain tumours, and non-Hodgkin lymphoma makes up a large share of childhood lymphomas. Unlike in adults, paediatric NHL is nearly always high-grade and fast-growing — yet with modern risk-adapted protocols it is also one of the more curable childhood cancers. (Source: figures reported by the American Cancer Society and reflected in NCCN and ESMO paediatric lymphoma guidance.)
Four types account for most childhood non-Hodgkin lymphoma. Confirming the exact type — through biopsy and molecular testing — is what lets the team match treatment intensity to the disease.
| Type | Cell of origin | Typical presentation | Key markers |
|---|---|---|---|
| Burkitt lymphoma | Mature B cell | Very fast-growing; often abdomen or head & neck | MYC gene change |
| Lymphoblastic lymphoma | Immature T (or B) cell | Often a mass in the chest; may affect breathing | T-cell / precursor markers |
| Diffuse large B-cell lymphoma | Mature B cell | Fast-growing nodal or extranodal mass | CD20 positive |
| Anaplastic large-cell lymphoma | T cell | Nodes, skin or other sites; systemic symptoms | CD30, ALK |
This table is a general guide; presentations and outcomes vary by individual. The exact type is confirmed by a pathologist on tissue, with immunophenotype and molecular testing, following NCCN and ESMO guidance.
We cover two of these in more depth on dedicated pages: Burkitt lymphoma in children and lymphoblastic lymphoma in children. For the Hodgkin form of childhood lymphoma, see Hodgkin lymphoma in children & teens.
Because paediatric NHL grows quickly, symptoms often develop over days to a few weeks. Where the signs appear depends on where the lymphoma is growing:
Most of these signs have ordinary causes, such as common childhood infections. But a lump that keeps growing, a swollen abdomen, or any breathing trouble should be assessed promptly. Talk to a CION specialist if you are worried about your child.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a childhood NHL diagnosis, want to understand your child's type, or need a second opinion before treatment? CION's team is here to help.
Confirming paediatric NHL — and pinning down its exact type and how far it has spread — takes a step-by-step pathway. CION delivers the imaging, biopsy coordination, bone-marrow diagnostics and molecular testing directly, and reviews every child at a tumour board, in line with NCCN and ESMO guidance.
Imaging can strongly suggest lymphoma, but only a tissue sample confirms the diagnosis and the exact subtype. A sample of an affected node or mass is examined by a pathologist, with immunophenotype and molecular testing — markers such as CD20, CD30, MYC and ALK — to distinguish Burkitt, lymphoblastic, large B-cell and anaplastic large-cell disease.
Because paediatric NHL can involve the bone marrow and central nervous system, a bone-marrow examination and a sample of spinal fluid are usually part of staging. These tests tell the team whether the disease has spread to these sites, which changes the treatment intensity.
Scans — including PET-CT — map how far the lymphoma has spread and provide a baseline to measure the response to treatment. Together, the biopsy, marrow and imaging results define the stage and risk group, which the tumour board uses to choose the right protocol. For deeper detail on staging and regimens, see the lymphoma treatment in Hyderabad page.
The plan depends on the type, stage and risk group, and every child is reviewed by CION's multidisciplinary tumour board before treatment starts. Paediatric NHL is treated mainly with drug therapy, because it responds so well — surgery is rarely needed beyond the diagnostic biopsy. The main building blocks are:
The backbone of treatment is combination chemotherapy, given over a defined period and tailored (risk-adapted) to the subtype and stage. Limited-stage disease may need a shorter, less intensive course, while more widespread disease needs more intensive therapy. CION's team delivers systemic therapy directly, with the supportive care a child needs to get through it. Specific regimen names and schedules are covered on the lymphoma treatment page.
Some B-cell types — such as Burkitt and diffuse large B-cell lymphoma — also receive antibody-based immunotherapy, for example an anti-CD20 monoclonal antibody, added to chemotherapy. This targets a marker on the surface of the lymphoma cells. CION delivers antibody immunotherapy directly.
Because paediatric NHL can spread to the brain and spinal fluid, treatment usually includes therapy directed at the central nervous system to prevent or treat spread there. This is a standard part of most childhood NHL protocols.
Radiation therapy (delivered with IMRT) is used selectively — for example for certain sites or emergencies — rather than routinely. For a child whose disease returns or does not respond, a stem-cell transplant may be considered; CION coordinates transplant through accredited partner facilities rather than delivering it in-house. Survivorship follow-up — watching long-term health after treatment — is managed by our team.
Outcomes for childhood NHL have improved dramatically over recent decades. Published paediatric series report survival for many childhood NHL types in the region of 80–90% or higher, especially for limited-stage disease — though figures vary by subtype, stage and individual factors, and no number is a promise for any one child. (Source: paediatric outcome data reported by the American Cancer Society and reflected in NCCN and ESMO paediatric lymphoma guidance.)
A childhood lymphoma diagnosis is overwhelming, and a second opinion can bring clarity and confidence. It is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service, and coordinates paediatric lymphoma care as a bridge into our Pediatric Cancer hub. You deserve a plan built around your child's healing, with transparent costs explained up front. Request your free second opinion or call 18002028726. You can also meet our lymphoma doctors and see our lymphoma hospital in Hyderabad.
Get a free written second opinion from CION's tumour board — especially valuable if the NHL subtype is uncertain or staging tests are not yet complete.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Childhood non-Hodgkin lymphoma (NHL) is a cancer that begins in the lymphocytes — the white blood cells of the immune system — and grows in lymph nodes, the chest, abdomen or other lymphatic tissue. It behaves very differently from adult NHL: in children it is usually fast-growing (high-grade) and spreads quickly, but it is also very responsive to treatment. The main paediatric types are Burkitt lymphoma, lymphoblastic lymphoma, diffuse large B-cell lymphoma and anaplastic large-cell lymphoma. Because it can move fast, prompt diagnosis matters. For the broader picture, see our overview of lymphoma in children and the main lymphoma hub.
There are four main types of paediatric NHL. Burkitt lymphoma is a very fast-growing B-cell type, often in the abdomen or head and neck, marked by MYC gene changes. Lymphoblastic lymphoma arises from immature T or B cells and often presents in the chest. Diffuse large B-cell lymphoma is another B-cell type that grows quickly. Anaplastic large-cell lymphoma is a T-cell type linked to the ALK marker. Identifying the exact type — through biopsy and molecular testing — is what lets the team match treatment intensity to the disease. Each type is treated on a distinct, established paediatric protocol.
Diagnosis begins with examination and imaging, then a biopsy of an affected node or mass to confirm lymphoma and identify the exact subtype. Because paediatric NHL can involve the bone marrow and central nervous system, a bone-marrow examination and sampling of spinal fluid are usually part of staging. Molecular and immunophenotype testing (markers such as CD20, CD30, MYC and ALK) pin down the type and guide the plan. Imaging — including PET-CT — maps how far the disease has spread. CION delivers biopsy coordination, bone-marrow exams, molecular testing and imaging, and every case is reviewed by a tumour board, in line with NCCN and ESMO guidance. Explore diagnostic detail on the lymphoma treatment page.
Childhood NHL is among the more treatable childhood cancers, and outcomes have improved markedly with modern protocols. Published paediatric series report survival for many childhood NHL types in the region of 80–90% or higher, particularly for limited-stage disease, though figures vary by subtype, stage and individual factors and should never be taken as a promise for any one child. Outcomes are best when the exact type is confirmed early and the child is treated on an established, risk-adapted protocol with strong supportive care. We do not guarantee outcomes; instead we set realistic, evidence-led expectations. Ask CION for a free second opinion and a clear explanation of your child's specific situation.
Paediatric NHL is treated mainly with chemotherapy — combination, risk-adapted regimens given over a defined period, tailored to the subtype and stage. Some B-cell types also receive antibody-based immunotherapy (for example an anti-CD20 monoclonal antibody). Treatment usually includes therapy directed at the central nervous system to prevent or treat spread there. Radiation is used selectively. Unlike solid tumours, NHL is rarely treated with surgery beyond the biopsy, because it responds so well to drug therapy. CION delivers chemotherapy, immunotherapy and radiation directly and coordinates stem-cell transplant through accredited partner facilities when needed. For specific regimen questions, see the lymphoma treatment page.
Because paediatric NHL grows quickly, symptoms often appear over days to a few weeks. Watch for a painless swollen lymph node or lump in the neck, armpit or groin that keeps growing; a swollen or painful abdomen, with fullness, vomiting or altered bowel habits (common in Burkitt lymphoma); or breathing difficulty, cough or facial swelling from a mass in the chest (common in lymphoblastic lymphoma). Fever, drenching night sweats, unexplained weight loss and tiredness can also occur. Many of these signs have ordinary causes such as infection, but a lump that keeps growing, or breathing trouble, should be assessed promptly. Talk to a CION specialist if you are worried.
Childhood NHL should be managed by a team experienced in paediatric cancer, with the ability to give risk-adapted chemotherapy, provide central-nervous-system-directed therapy, and support a child through intensive treatment. CION coordinates paediatric lymphoma care as a bridge into dedicated childhood-cancer services — see our Pediatric Cancer hub. Our team delivers chemotherapy, antibody immunotherapy, radiation, biopsy and bone-marrow diagnostics and survivorship follow-up directly, coordinates transplant with accredited partners, and reviews every child at a multidisciplinary tumour board. You can also meet the lymphoma specialists and learn about our lymphoma facilities in Hyderabad.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.